Serum Level of Macrophage Migration Inhibitory Factor in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease

    March 2014 in “ Journal of Clinical Laboratory Analysis ”
    Doreen N. Younan, Naglaa Agamia, Adel Elshafei, Nancy Ebeid
    TLDR Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
    The study investigated serum levels of Macrophage Migration Inhibitory Factor (MIF) in Egyptian patients with alopecia areata (AA) and found significantly higher MIF levels in AA patients compared to healthy controls. There was a positive correlation between MIF levels and the clinical severity of AA, with higher levels associated with more severe cases. Additionally, MIF levels negatively correlated with patient age and positively with disease duration. These findings suggested that MIF could be a crucial biomarker for assessing AA severity and a potential target for future therapies.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    3 / 3 results

      community The Worst Hair Loss Condition You (MAY) have: LPP

      in Research/Science  43 upvotes 3 months ago
      Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 4 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community Verteporfin and Microneedling

      in Treatments 6 months ago
      Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

    Related Research

    1 / 1 results